Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2004

View Archived Issues

In vivo characterization of a rapid-acting thyroid hormone derivative

Chemokine microbicide formulation effective against HIV-1 in macaques

Influenza vaccine from Aventis now available for shipping

Dual neuroprotection from oxygen and nitrogen reactive species

PEP-005 shows high selectivity against leukemia

New phase I study of AT-1001 for Fabry's disease

Phase I studies begin for ABT-894 for neuropathic pain

OrthoLogic completes acquisition of Chrysalis BioTechnology

New indication approved for Hyzaar

European recommendation for extended dosing of Aranesp

GlycoGenesys enters agreements to close on funding from institutions

Yakult Honsha and Taiho to copromote oxaliplatin in Japan

Portola licenses Millennium's Factor Xa inhibitor program

Five series of chemokine CCR5 antagonists presented by GSK

AstraZeneca presents novel GSK-3 inhibitors for AD and other uses

Japanese researchers prepare and test a new antineoplastic antibiotic

New KDR and FGFR inhibitors with potential in solid tumor therapy

New epothilone derivatives in early development at Novartis

New glucagon antagonists discovered by Novo Nordisk scientists

Novel PAI-1 inhibitors produced by the microorganism Stachybotris atra

Human multidrug resistance protein 1 targeted in malignant cells

Frovatriptan provides relief for menstrual associated migraine

Merck & Co. and DOV enter agreement for triple uptake inhibitor development

NPS to promote Amgen's Kineret to rheumatologists

Approvable letter for ZyLET

Sinovac's phase I SARS study progresses

Dosing begins in phase I study of the thrombin inhibitor ARC-183

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...